Sight Sciences, Inc. (NASDAQ:SGHT) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Sight Sciences’ Third Quarter 2023 Earnings Results Call. At this time, all participants are in a listen-only mode. After the speakers presentation there will be a question-and-answer session. [Operator Instructions]. Please […]
Blogs | | Ideally, corneal cross-linking is offered as an early intervention for keratoconus as soon as there is evidence of progression and before significant vision loss or ectasia. But what if you see a patient with a cornea that is already quite thin?
NDA Submission for Nyxol for RM and Initiation of VEGA-2 on Track for Q4 2022 Topline Data from ZETA-1 Phase 2b Trial of Oral APX3330 Expected in Early.
Highlighting latest clinical findings, including comparative efficacy for ocular itch relief between Pataday Once Daily Relief Extra Strength and an oral antihistamine Forthcoming innovations
21.10.2022 - NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) - Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet delivery system for use both in combination with its own drug-device therapeutic programs as well as .